Evidence map›Paper›PMID 35850864›Full record

ArticleBMC urology2022

Clinicopathologic, treatment and prognosis study of 46 Xp11.2 translocation/TFE3 gene fusion renal cell carcinomas.

Jiale Zhou, Ling Zhao, Zhaolin Yang, Yonghui Chen, Xiaorong Wu, Wei Xue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Diagnostic performance and prognostic value of preoperativeCancer imaging : the official publication of the International Cancer Imaging Society · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiale Zhou *Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.
Ling Zhao *Department of Pathology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.
Zhaolin YangDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.
Yonghui ChenDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.
Xiaorong WuDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. xiaorong541@126.com.
Wei XueDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. xuewei@renji.com.

Funding

Shanghai Hospital Development Center 16CR3062BShanghai Hospital Development Center SHDC2020CR6008Shanghai Jiao Tong University YG2017QN46
6 · The paper itself

Abstract

purposeTo report the clinicopathological features and mid- to long-term oncologic results of Xp11.2 translocation/transcription factor E3 (TFE3) gene fusion renal cell carcinomas (Xp11.2 translocation RCCs) in a single large-volume centrecentre.

methodsClinical and follow-up data of 46 patients who were diagnosed with Xp11.2 translocation RCC and underwentunderwent surgical intervention were retrospectively reviewed.

resultForty-six Xp11.2 translocation RCC patients were identified from 4218 renal tumour patients who were underwentunderwent surgery in our centrecentre from Jan. 2014 to Apr. 2020. The incidence of Xp11.2 translocation RCCs in our centre was 1.09%. During a median follow-up period of 30.5 months, 4 patients died of the disease. The total median overall survival and cancer specific survival were 30.0 months and 24.0 months, respectively. The 1-year, 3-year and 5-year OS rates were 97.4%, 88.8%, and 88.8%, respectively. In multivariable analysis, displaying symptoms when diagnosed (p = 0.019), lymph node metastasis (p = 0.002) and distal metastasis (p = 0.020) were identified as risk factors for poor prognosis.

conclusionXp11.2 translocation RCC is a type of renal cell carcinoma with a relatively low incidence and various prognoses. Early-stage Xp11.2 translocation RCCs have a similar prognosis to most typical RCCs, but late-stage Xp11.2 translocation RCCs can lead to poor oncological outcomes.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsChromosomes, Human, XGene FusionHumansPrognosisRetrospective StudiesTranslocation, GeneticBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsTFE3 protein, humanRCCTFE3 geneTranslocational renal cell carcinomaXp11.2

Identifiers

PMID35850864
PMCPMC9295427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.